Lupus Nephritis Drugs Market Size Worth USD 5.17 Billion by 2034 | CAGR: 10.15%
The global lupus nephritis drugs market size is expected to reach USD 5.17 billion by 2034, according to a new study by Polaris Market Research. The report “Lupus Nephritis Drugs Market Share, Size, Trends, & Industry Analysis Report By Drug Class, By Route of Administration, By Distribution Channel, and By Region; Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Lupus nephritis drugs market growth is gaining traction from recent regulatory and commercial milestones. Gazyva (obinutuzumab) secured U.S. and EU approval for adults with active lupus nephritis in October 2025, while Aurinia Pharmaceuticals reported a 19% rise in total revenue for the second quarter of 2026, led by Lupkynis.
Competition among approved products is increasingly shaped by lifecycle expansion and combination use rather than by new entrants alone. Aurinia Pharmaceuticals has started the Phase 4 PRESERVE study combining Lupkynis with belimumab, obinutuzumab, or anifrolumab. Roche is also pursuing a broader systemic lupus erythematosus label for Gazyva, with an FDA decision expected by December 2026.
The pipeline is also becoming more diverse. Novartis's ianalumab and AstraZeneca's anifrolumab are the most advanced candidates in Phase III, while cell therapies from Autolus, Cabaletta Bio, Kyverna Therapeutics, and Adicet Bio are progressing through earlier clinical stages. Autolus expects data from its obe-cel pivotal program in 2028, while Cabaletta Bio is pursuing an FDA-aligned registrational cohort in lupus nephritis. Outcomes from these programs will determine whether a fourth approved mechanism reaches the market.
Questions? Request a sample or make an inquiry before buying this report by clicking the link below: Lupus Nephritis Drugs Market Report
The market is also being shaped by the range of delivery formats now available to patients and prescribers. Oral, subcutaneous, and intravenous regimens now coexist, and manufacturers are competing on dosing convenience as well as clinical efficacy. Together with a deepening pipeline, this is making the therapeutic landscape more competitive.
Lupus Nephritis Drugs Market Report Highlights
- Anti CD20 monoclonal antibodies dominated the drug class segment with 14.56% share in 2025, backed by strong complete renal response data for obinutuzumab in the Phase III REGENCY trial.
- Calcineurin inhibitors are projected to record 10.84% CAGR during the forecast period, supported by extended patent protection for voclosporin, with a settlement blocking U.S. generic entry until December 2036.
- Oral administration led the route of administration segment with 47.62% revenue share in 2025. It is fueled by the expanding availability of Lupkynis beyond the U.S., including Japan.
- Subcutaneous administration is projected to record a CAGR of 14.72% during the forecast period, driven by weekly, self-administered dosing of subcutaneous Benlysta.
- Hospital pharmacies accounted for the leading distribution channel with 41.18% share in 2025, while specialty pharmacies are projected to register 12.48% CAGR as prescriptions for high-priced targeted therapies increasingly route through specialty channels.
- North America dominated the global lupus nephritis drugs market share with 43.08% in 2025. All three targeted therapies are FDA approved for active lupus nephritis, giving the region an early commercial footing that boosts market growth.
- The market in Asia Pacific is projected to register the fastest CAGR of 12.74% during the forecast period, supported by Japan's approval of oral voclosporin and the scope for further regulatory approvals across China and India.
- A few global key market players include AbbVie Inc.; Amgen Inc.; AstraZeneca PLC; Aurinia Pharmaceuticals Inc.; Biocon Limited; Biogen Inc.; Bristol-Myers Squibb Company; Cabaletta Bio, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd (Genentech, Inc.); GSK plc; Kyverna Therapeutics, Inc.; Novartis AG; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Teva Pharmaceutical Industries Limited; and Viatris Inc.
Lupus Nephritis Drugs Market report on the drug class, route of administration, distribution channel, and region:
By Drug Class Outlook (Revenue, USD Billion, 2021–2034)
- Calcineurin Inhibitors
- Anti CD20 Monoclonal Antibodies
- BLyS Inhibitors
- Conventional Immunosuppressants
- Corticosteroids
By Route of Administration Outlook (Revenue, USD Billion, 2021–2034)
- Oral
- Intravenous
- Subcutaneous
By Distribution Channel Outlook (Revenue, USD Billion, 2021–2034)
- Hospital Pharmacy
- Specialty Pharmacy
- Retail Pharmacy
By Regional Outlook (Revenue, USD Billion, 2021–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Vietnam
- Australia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
